# CJC-1295 References: The Peer-Reviewed Studies Behind Every Claim

> CJC-1295 references: the full citation list behind this site, with DOIs and PubMed links — Teichman 2006, Jette 2005, Ionescu/Frohman 2006, Alba 2006, and the supporting GHRH-analog literature.

The peer-reviewed studies and reviews this console draws from, with journal, year, DOI, PMID, and a direct link. The pulsatility, half-life, and synergy claims all resolve here.

## How this reference list is organized

Every quantitative claim in this CJC-1295 console maps to a numbered citation below. The core human pharmacokinetic findings — the 5.8-to-8.1-day half-life, the +7.5-fold basal GH, the +45% IGF-1, the preserved pulse pattern — come from references 1 and 3 [1][3]. The preclinical bioconjugation and receptor data come from references 2 and 4 [2][4]. The remaining entries cover the proteomic, analytical, synergy, and review literature that situates the compound in its class. Where a study is paywalled, the linked abstract and DOI remain the canonical record.

## The human evidence (references 1, 3, 5)

Three human studies carry most of what is reliably known. Teichman 2006 established the pharmacokinetics — the dose-dependent multi-day rise in GH and IGF-1 and the 5.8-to-8.1-day half-life [1]. Ionescu/Frohman 2006 established the pulsatility result — basal GH up roughly 7.5-fold and IGF-1 up about 45% at one week, with pulse frequency and amplitude unaltered [3]. Sackmann-Sala 2009 added the proteomic dimension, finding reproducible serum-protein shifts that correlated with IGF-1 — candidate biomarkers of axis activation [5].

All three are early-phase work in healthy adults. None is a large efficacy or long-term safety trial, and that absence is itself part of the record this site reports [1].

## The preclinical and class literature (references 2, 4, 6-15)

The preclinical foundation is Jette 2005, which identified CJC-1295 as the lead long-lasting GRF analog and showed the 4-fold GH AUC advantage over unconjugated peptide in rats [2], and Alba 2006, which showed once-daily CJC-1295 normalized growth in GHRH-knockout mice [4]. The synergy literature behind the ipamorelin pairing — the GHRH-plus-GHRP supra-additive effect, ghrelin potentiation, and differential pulsatile control — is references 8, 9, and 10 [8][9][10].

The analytical entries (references 6, 11, 12) document how CJC-1295 and its class are detected, including the LC-MS/MS identification of the compound in a seized preparation [6]. References 7 and 13 cover the episodic-versus-continuous GHRH physiology and GHRH-analog wound-healing work [7][13]. References 14 and 15 are recent reviews situating GHRH analogs in endocrinology and aging research [14][15].

## References

[1] Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. https://pubmed.ncbi.nlm.nih.gov/16352683/
[2] Jette L, Leger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. https://pubmed.ncbi.nlm.nih.gov/15817669/
[3] Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. https://pubmed.ncbi.nlm.nih.gov/17018654/
[4] Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. https://pubmed.ncbi.nlm.nih.gov/16822960/
[5] Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. https://pubmed.ncbi.nlm.nih.gov/19386527/
[6] Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal. 2010;2(11-12):647-650. https://pubmed.ncbi.nlm.nih.gov/21204297/
[7] Greater efficacy of episodic than continuous growth hormone-releasing hormone (GHRH) administration on GH release. J Clin Endocrinol Metab. 1996;81(3). https://pubmed.ncbi.nlm.nih.gov/8772566/
[8] Determinants of GH-releasing hormone and GH-releasing peptide synergy in men. Am J Physiol Endocrinol Metab. 2009. https://pubmed.ncbi.nlm.nih.gov/19240251/
[9] Ghrelin and growth hormone (GH) secretagogues potentiate GH-releasing hormone (GHRH)-induced GH secretion. Endocrinology. 2002. https://pubmed.ncbi.nlm.nih.gov/12446584/
[10] Differential pulsatile secretagogue control of GH secretion in healthy men. Am J Physiol Regul Integr Comp Physiol. 2013. https://pubmed.ncbi.nlm.nih.gov/23485864/
[11] Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Test Anal. 2021. https://pubmed.ncbi.nlm.nih.gov/34665524/
[12] Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-MS. Anal Bioanal Chem. 2016. https://pubmed.ncbi.nlm.nih.gov/26879649/
[13] Agonistic analogs of growth hormone releasing hormone (GHRH) promote wound healing. Oncotarget. 2016. https://pubmed.ncbi.nlm.nih.gov/27494841/
[14] Granata R, Leone S, Zhang X, Gesmundo I, et al. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025;21(3):180-195. https://pubmed.ncbi.nlm.nih.gov/39537825/
[15] Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. Front Aging. 2026. https://pubmed.ncbi.nlm.nih.gov/42021992/

---

A research console that reads the published CJC-1295 record straight — basal GH, IGF-1, and the DAC-versus-no-DAC half-life logged to source and tagged by evidence strength, with no clinic behind the console and no script filled here.